ArticleFrontiers in immunology2025
Clinical features and influencing factors analysis of T-cell large granular lymphocytic leukemia complicated with pure red cell aplasia.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study systematically characterized the key clinical features and influencing factors of patients with T-LGLL-PRCA, aiming to provide evidence to improve clinical diagnostic and therapeutic strategies. Methods: Clinical characteristics were retrospectively compared between patients with T-LGLL-PRCA (n=15) and those without PRCA (T-LGLL-Non-PRCA, n=25). Risk factors for the development of T-LGLL-PRCA were evaluated using univariate and multivariate logistic regression analyses. Results: This study retrospectively included a total of 40 patients with T-LGLL, of whom 15 were classified into the T-LGLL-PRCA group, accounting for one-third of the entire cohort. The median age of patients in the T-LGLL-PRCA group was 68 years, with a relatively high proportion aged ≥65 years, and the majority were female. The most common symptoms included fatigue, dizziness, and palpitations. The major comorbidity was thrombocytopenia. Positivity for EBV and ANA was frequently observed. Mutations in TET2 exon 11 and exon 3 were the most frequently detected genetic variants. At the molecular level, clonal rearrangements of the TCRβ and TCRγ genes were most commonly observed. Moreover, a substantial proportion of patients displayed a TCR γδ immunophenotype. Significant differences between groups were observed in circulating T-LGL count, Hemoglobin (HB), Hematocrit (HCT), Reticulocyte Count (RNC), Erythropoietin (EPO) levels >750 mIU/mL, and Immature Reticulocyte Fraction (IRF) ( Conclusion: RNC is an independent influencing factor for the development of T-LGLL-PRCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.